Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNK01002 in Malignant Myeloid Hematologic Neoplasms
NCT04896112Phase 1Withdrawn
- Sponsor
- Lynk Pharmaceuticals
- Start
- Apr 2021
- Primary completion
- Oct 2022
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of LNK01002 in myeloid neoplasms, acute myeloid leukemia (AML), primary myelofibrosis (PMF) and 2 more (10 arms), sponsored by Lynk Pharmaceuticals. Primary endpoints: Safety and tolerability of LNK01002 at 31 days, Maximum Tolerated Dose and/or Recommended Phase II Dose at 31 days and 1 more. Planned start Apr 2021; status: withdrawn.
02
Drugs
LNK01002
03
Conditions
myeloid neoplasmsacute myeloid leukemia (AML)primary myelofibrosis (PMF)polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT04896112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04896112.